RxDoctor Payments Data

Henry Hooker, MD

Neurology · Oak Ridge, TNNPI 1700963857

Payments from drug & device makers

$497in general payments, 2019–2025

Across 30 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$266
  • Impel Pharmaceuticals Inc.$132
  • Supernus Pharmaceuticals, Inc.$36
  • Pfizer$32
  • Lilly USA, LLC$17
  • Bausch Health US, LLC$14

What the payments were for

  • Food & beverage$497100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$497 in reported general payments places this provider in the 30th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$190,767
Medicare patients
114
Services billed
25,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm336$268,579
UbrelvyUbrogepant85$115,646
QuliptaAtogepant57$63,071
Aimovig AutoinjectorErenumab-Aooe37$47,203
Emgality SyringeGalcanezumab-Gnlm38$41,713
Nurtec OdtRimegepant Sulfate24$33,182
BotoxOnabotulinumtoxina15$22,145
Ajovy SyringeFremanezumab-Vfrm25$21,646
Ajovy AutoinjectorFremanezumab-Vfrm20$17,716
Sumatriptan Succinate124$5,789
Topiramate154$2,327
Baclofen97$1,772
Naratriptan Hcl46$1,643
Diclofenac Potassium14$1,416
Gabapentin119$1,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$32$33,18224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 361 neurology providers in Tennessee.

Other neurology in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →